Fly News Breaks for February 20, 2019
Feb 20, 2019 | 08:30 EDT
Barrington analyst Michael Petusky lowered his price target for Tivity Health (TVTY) to $40 after the company's fiscal 2019 outlook came in below expectations. The analyst also believes the pending Nutrisystem (NTRI) acquisition is weighing on Tivity's valuation. While there is "certainly a rationale for the deal, there is also material risk that attends this transaction and much skepticism among investors," Petusky tells investors in a research note. He maintains an Outperform rating on the shares.
News For TVTY;NTRI From the Last 2 Days
There are no results for your query TVTY;NTRI